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Abstract
Understanding the circumstances under which exposure to transmissible spongiform encephalopathies (TSEs) leads to
infection is important for managing risks to public health. Based upon ideas in toxicology and radiology, it is plausible that
exposure to harmful agents, including TSEs, is completely safe if the dose is low enough. However, the existence of a
threshold, below which infection probability is zero has never been demonstrated experimentally. Here we explore this
question by combining data and mathematical models that describe scrapie infections in mice following experimental
challenge over a broad range of doses. We analyse data from 4338 mice inoculated at doses ranging over ten orders of
magnitude. These data are compared to results from a within-host model in which prions accumulate according to a
stochastic birth-death process. Crucially, this model assumes no threshold on the dose required for infection. Our data
reveal that infection is possible at the very low dose of a 1000 fold dilution of the dose that infects half the challenged
animals (ID50). Furthermore, the dose response curve closely matches that predicted by the model. These findings imply
that there is no safe dose of prions and that assessments of the risk from low dose exposure are right to assume a linear
relationship between dose and probability of infection. We also refine two common perceptions about TSE incubation
periods: that their mean values decrease linearly with logarithmic decreases in dose and that they are highly reproducible
between hosts. The model and data both show that the linear decrease in incubation period holds only for doses above the
ID50. Furthermore, variability in incubation periods is greater than predicted by the model, not smaller. This result poses
new questions about the sources of variability in prion incubation periods. It also provides insight into the limitations of the
incubation period assay.
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Introduction
During the 1980s and 1990s, millions of Britons were orally
exposedtobovinespongiformencephalopathy(BSE),yetfewerthan
200 individuals have been diagnosed with variant Creutzfeldt–
Jakob disease (vCJD). Understanding the circumstances under
which exposure to transmissible spongiform encephalopathies
(TSEs) leads to infection is important for managing risks to humans
and animals from TSEs. With regard to the vCJD epidemic, it is
clear that the species barrier was important in curtailing cases, but
other mechanisms may also have played a role. For example, it is
unclear how the probability of infection changes with the level of
TSE exposure, especially at very low doses. Based upon ideas in
toxicology and radiology [1] it is plausible that exposure to harmful
agents,includingTSEs,iscompletely safe atlowenough doses[2,3],
but the existence of a threshold dose below which the probability of
infection is zero is uncertain.
In the case of TSEs, there is some evidence to suggest such a
threshold may exist. Mathematical models have been used to
investigate the replication kinetics of prions – a general term for
the proteinaceous etiological infectious agents of TSEs. It has been
proposed that the smallest such infectious agent of TSEs is a
polymer, made up of several monomers of PrP
Sc [4–6], the
abnormal form of the prion protein. In that model the rapid
conversion of the normal form of the prion protein (PrP
C) to the
abnormal form occurs only in the presence of polymers of a certain
length. Polymers shorter than that length do not lead to rapid
replication; instead they are unstable and can only grow to the
required length through slow monomer addition. This mechanism
was originally proposed to explain why spontaneous disease is
so rare and yet disease appears to progress ‘inevitably after
inoculation’ [6]. However, other evidence supports this mecha-
nism. Namely it explains exponential accumulation of infectious
material within a host [7,8], prion strain diversity [9,10], the linear
appearance of fibrils [11,12], some results from sonication
experiments [13], and the failure to dissociate infectivity from
aggregated forms of the prion protein [14]. A plausible
consequence of this model is that there exists a threshold effect,
such that if a host is infected with a concentration of PrP
Sc
monomers that is lower than the critical polymer length then the
infection does not propagate. Nevertheless the exact form or forms
of the infectious agent of TSEs remains uncertain and so too does
the mechanism of replication. Throughout this paper we use the
term prion to describe a unit of the infectious agent that is capable
of producing an infectious copy of itself.
We investigate the existence of a threshold infectious dose
of prions using data from a very large collection of experiments
(N=127) in which mice were inoculated with varying doses of
tissue from mice infected with mouse-passaged scrapie isolates. We
also use these data to understand more about TSE incubation
periods. The data includes records of whether each mouse became
ill, and the incubation periods for those mice that developed
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prion replication. In the model the onset of disease is defined as the
moment at which the number of prions reaches a predetermined
limit [15]. Crucially, our model does not assume the existence of a
threshold dose below which the probability of infection is zero.
The three main questions that we address using the data are
summarised here:
1. Is there evidence of a threshold dose of prions below which the
probability of infection is zero?
2. How does mean incubation period change with dose; is it true
that mean incubation period decreases linearly with logarith-
mic increase in dose?
3. How does the variation in incubation period change with dose;
is it true that TSE incubation periods are highly reproducible?
To address the first of these questions we measure how the
probability of infection in mice changes with dose. We show that
infection is still possible at very low doses indeed, namely three
orders of magnitude lower than the ID50 – the dose at which 50%
of challenged hosts become infected. Furthermore the shape of
this dose-response curve is consistent with the model of prion
replication in which there exists no threshold dose of prions.
Taken together these findings imply that there is no safe dose of
prions. We find evidence to support the assumption of a linear
relationship between dose and probability of infection in assessing
the risk from low dose exposure.
In the remaining two questions we challenge two common
assertions. The first is that mean incubation periods decrease
linearly with logarithmic decrease in the dose of infectious
material. The model predicts that the linear decrease in incubation
period holds only for doses above the ID50; for doses below the
ID50, incubation period is relatively invariant to dose. We observe
precisely this pattern in the data. The second assertion is that
incubation periods of prion diseases are highly reproducible. We
measure the variability in incubation periods and compare it
to model predictions. We find that although murine scrapie
incubation periods appear very reproducible they are actually
markedly more variable than predicted by the model. These
findings have implications for prion studies that use incubation
periods as a method to quantify the dose of an inoculum,
emphasising that this method is only reliable at doses above the
ID50. Furthermore they reveal a new perspective on prion
incubation periods asking ‘why are they so variable?’ rather than
‘why are they so constant?’
Results
There is no safe dose of prions
To investigate evidence for the existence of a threshold dose of
prions below which the probability of infection is zero we used
a mathematical model and data collated from 127 different
experiments in the murine scrapie model [16–21]. The experi-
ments differed by mouse breed, tissue type, scrapie strain and
route of inoculation, and within each experiment mice were
infected at varying doses (10 fold dilutions). In total 4338 mice
were inoculated. Incubation periods were recorded for those mice
that showed clinical symptoms and the majority of mice were also
tested post-mortem for pathological signs of scrapie.
First we analysed how the probability of infection changed with
the dose of the inoculum. To enable us to meaningfully collate the
data from different experiments we made use of the concept of the
relative dose. This required us to calculate the ID50 for each
experiment. However, for eight experiments it was not possible to
estimate the ID50 with reasonable accuracy, thus data from these
experiments (195 mice) were excluded from further analysis
leaving 4143 mice to analyse. The rules used for the ID50
calculations are described in Figure S1. Once ID50s were
estimated the ‘absolute dose’ within each experiment was then
assigned a ‘relative dose’ – a relative dose of 0 is equal to the ID50,
the positive integers are sequentially tenfold more concentrated
than the ID50 and the negative integers, tenfold more dilute. More
details of these experiments have been provided elsewhere [17]. In
that study the data were also converted to the relative dose scale
where it was shown that under this transformation there are no
systematic trends that render the grouping of data from different
experiments invalid.
Figure 1A and Table 1 show how the probability of infection
changes according to relative dose when data from all of the
murine experiments are collated. There is evidence of infection at
very low doses indeed – three orders of magnitude below the ID50
(relative dose -3). At the lowest dose tested (relative dose -4), no
mice were infected, however only eleven mice were challenged.
Only one out of 92 mice tested positive at relative dose -3,
indicating that the lack of infections observed at relative dose -4
could easily be explained by the small sample size. These data
therefore do not provide any evidence that there exists a threshold
dose below which the probability of infection is zero. Instead, they
suggest that as dose decreases the probability of infection simply
becomes smaller. Similarly, as dose increases the probability of
infection simply increases. To demonstrate this under a more
formal setting we compare the ‘dose-response’ data to predictions
made by a very simple stochastic within-host model of prion
propagation.
In the model the host is inoculated with a certain number, x,o f
prions. Following inoculation, the total number of prions, n(t), at
time t, changes because of two processes: prions can interact with
uninfectious PrP
C monomers to create more prions at rate b per
prion, or they can ‘die’ at rate m per prion. Death could represent
clearance of the prions and/or conformational change back to
PrP
C monomers, but the process is immaterial since we assume
no restriction on the availability of PrP
C monomers. Thus the
replication dynamics of each prion is independent. This model is
precisely a stochastic linear birth-death process as represented in
Figure 2A. The onset of disease is assumed to occur once the
number of prions has reached a predetermined ‘disease limit’
(Figure 2B black jagged line, n(t)=L) [15]. However, since this is a
stochastic process that includes death of prions, the prion
population can also become extinct (n(t)=0), leaving the host
uninfected (Figure 2B grey jagged line). If the model is considered
for a fixed period, there is a third option – at cessation of the
experiment the host is infected, but disease has not occurred. This
possibility corresponds to the small number of mice with each dose
that showed pathological lesions at post-mortem but had not
showed any signs of disease. This model was chosen because it is
the simplest system in which prion numbers grow exponentially
[7,8], the onset of disease is not certain, and infection probabilities
are not governed by a dose threshold.
To compare the model to the dose-response data (Figure 1A,
circles) we made use of the following expression that describes how
the probability of infection, p, is expected to change with relative
dose (RD): p~1{0:510RD
. The derivation of this expression is
provided in Text S1 [22,23]. The analytic form and Figure 1A
(black line) shows that the probability of infection changes
sigmoidally with relative dose and is independent of other factors.
For this curve there is no dose where the probability of infection is
exactly zero or exactly one. Simply, the probability of infection
tends to one as dose increases above the ID50 and tends to zero as
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PLoS ONE | www.plosone.org 2 August 2011 | Volume 6 | Issue 8 | e23664Figure 1. Data (circles) and model fits (solid black lines) showing how the proportion of mice infected and the expectation and
variance of the incubation period vary according to the relative dose. A) The proportion of mice infected increases as the relative dose
increases. The data reveals a sigmoidal pattern that fits well with the model that predicts that infection probability approaches zero at low doses and
approaches one at high doses. In the data, infection probability was non zero as low as relative dose –3, but at relative doses –4 (the lowest dose
tested) no mice were infected. However, the data at relative dose -3 and the model both indicate that a much larger sample size than the one used
(N=11) would be needed to find at least one infected mice at this dose. These results are consistent with the hypothesis that there exists no safe
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an explanation of how the probability of infection can tail off
dramatically at low doses in the absence of a threshold. The
comparison in Figure 1A shows that the model fits the data well.
Note that since the data is presented as a function of relative dose
and since the expression for p is solely dependent upon relative
dose, the data and model are compared directly without the
need to fit any parameters. The model also suggests that it is
unsurprising that no mice were infected at relative dose –4. With a
predicted probability of infection of 7610
25, a sample size of
14000 mice would be required to find only one positive. Only 11
mice were tested at that dose.
To compare the model and observations further, we trans-
formed the infection probability data according to the function
f(p)~log10 {ln(1{p) ðÞ and plotted it against relative dose (open
circles, Figure 1B). If the data were exactly consistent with the
model this transformation would transform the data to a straight
line. On this scale the data are close to linear from relative doses
–2 to 1, but either side of these doses the data are less consistent
with the model. It is noteworthy that where this happens at relative
dose –3 the probability of infection is slightly greater than predicted
by the model. This is counter to what would be expected if
infection probability was governed by a threshold dose. For
completeness, we have also transformed the data according to the
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22 294 6 5 0 0?020 333 3316 -
21 591 64 59 38 0?108 357 25491 2503
0 712 375 352 330 0?527 337 17041 2935
1 644 604 589 584 0?938 290 10651 1354
2 461 452 439 439 0?980 256 9092 936
3 337 333 329 329 0?988 240 11041 270
4 207 205 203 203 0?990 200 7060 970
5 9 09 0 9 08 9 1 ?000 184 1329 136
TOTAL 3439 2130 2066 2012 0?619 271 13174 1270
At each relative dose the proportion infected (column 6) was estimated from all mice inoculated at that relative dose from 119 experiments for which an ID50 could be
calculated. The mean (column 7) and variance (column 8) of the incubation period were estimated from all mice infected at that relative dose for which incubation
period data were available (column 4). Part of the variability in incubation periods at each group is because of variability in the average incubation period between
experiments. Column 9 shows the variance at each relative dose, excluding between-experiment variability in the average incubation periods. This metric was derived
by first grouping mice according to experiment number and relative dose. For each mouse with an incubation period, we then calculated the difference between its
incubation period and the mean incubation period of mice in that experiment-dose group. Data from experiment-dose groups for which there were fewer than two
infected mice with an incubation period were excluded from this analysis (column 5). At each relative dose, the variance of these differences was then calculated
(column 9).
doi:10.1371/journal.pone.0023664.t001
dose of prions. The modelled infection probability has no free parameters (p~1{0:510RD
) rendering the agreement between theory and data the
more convincing. B) Two transformations are applied to the probability of infection data and the results are plotted against relative dose. Plotted as
open circles is the transformation log10 {ln(1{p) ðÞ . Using this transformation a straight line would indicate that the data are consistent with the
model. Plotted as filled circles is the logit transformation, ln p=(1{p) ðÞ , a function that is typically used to transform s-shaped data. Both
transformations show similar results – plots that are close to linear from relative doses -2 to 1. Either side of these doses the data are almost linear, but
less consistent with the model. Interestingly, at relative dose {3 the probability of infection is slightly greater than predicted by the model. This is
counter to what would be expected if infection probability was governed by a threshold dose. C and D) The probability of infection is plotted against
dose in ID50s for low relative doses (C, #0.1 ID50s) and higher relative doses (D; #10 ID50s). These figures shows how the model assumes a linear
relationship between dose and probability of infection at low doses (black lines). The data also supports the assertion that the probability of infection
– whilst marginally greater than predicted by the model – is approximately linear at low doses. For comparison, the red line in each of these figures
represents a linear relationship which necessarily has 0% probability at no dose and 50% probability of infection at the ID50. This comparison reveals
that as dose increases, the relationship becomes increasingly less linear, particular beyond the ID50. E) The mean incubation period is dose-
dependent. For relative doses above zero (the ID50), mean incubation period decreases linearly with the relative dose, whereas for relative doses
below zero, it is relatively invariant to the relative dose. The model is fitted to the incubation period data using least squares to estimate two
parameters. F) The observed variation in incubation periods is markedly greater than the variance predicted by the model. In this panel the circles
show the observed variance of the difference from the group mean incubation period for mice from groups with at least two mice (Table 1, column
9). The black line represents model predictions of the variation of the incubation period. Since the net growth rate (b-m) determines the maximum
variance (see Figure 3C), this model prediction assumes that the net growth is equal to that estimated from the mean incubation period data shown
in panel E.
doi:10.1371/journal.pone.0023664.g001
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function that is typically used to transform sigmoidal data. This
transformation shows a similar pattern. In summary, by comparing
the murinedata to the model,we find no evidence that there exists a
safe dose of prions.
In risk assessments of exposure to TSE infectivity it is important
to understand the relationship between dose and the probability of
infection. The relationship can be used to translate exposure levels
into predicted number of infections. Many such studies assume,
either implicitly or explicitly, that the relationship between dose
and infection probability is linear, i.e. doubling the dose leads to
double the infection probability [24–28]. In other studies, non-
linear relationships have been explored [29,30]. In the context of
TSE risk assessments it is often appropriate to assume that, even if
many hosts are exposed, each host has only a low level of
exposure. Figures 1C and 1D show the dose response curve
replotted as a function of the dose in terms of number of ID509s.
These figures reveal that the model relationship between dose and
probability of infection is linear at low doses (black lines). This can
be confirmed mathematically (Text S1, expression 12) [23] and is
intuitively obvious given the underlying assumption of our model
that the replication dynamics of each prion is independent. The
data also supports the assertion that the probability of infection –
whilst marginally greater than predicted by the model – is
approximately linear at low doses. For comparison, the red line in
each of these figures represents a linear relationship which
necessarily has 0% probability at no dose and 50% probability
of infection at the ID50. This comparison highlights that that as
dose increases, the observed relationship becomes increasingly less
linear, particular beyond the ID50. In summary, for low dose
exposure we find evidence in support of risk assessments assuming
a linear relationship between dose and infection probability. Thus,
doubling the dose leads to double the infection probability. As dose
increases this relationship breaks down, particularly above the
ID50. Use of the linear relationship at these higher doses is likely
to overestimate, rather than underestimate, risk.
Incubation period decreases linearly with relative dose
only for doses above the ID50
There has been a long understanding that TSE incubation periods
decrease approximately linearly with every tenfold increase in dose
and are highly reproducible between hosts [6,17,31]. As such,
incubation periods have been used in diagnostic tests as a proxy for
dose [32,33]. Deepening our understanding of TSE incubation
periods therefore has important implications for ensuring accurate
diagnostic tests. It may also lead to clues about prion replication
mechanisms.
We have used the model and murine data to investigate how
mean incubation periods change with dose. The deterministic
form of the model (dn=dt~(b{m)n) predicts that prion numbers
grow exponentially (n(t)~n(0)e(b{m)t) and therefore for all doses,
incubation period should decrease linearly with logarithmic
increase in dose, i.e. decrease linearly with relative dose. Each
unit increase in relative dose should lead to a reduction of the
incubation period by a value of ln(10)=(b{m), where b{m is the
net growth rate of prions. At high doses this is what we see
(Figure 1E). However, prion replication is a stochastic process and
at low doses this stochasticity disrupts the dose-incubation period
relationship. At doses below the ID50 the incubation period is
predicted to be invariant to dose (Figures 3A and 3B) and this
prediction is fulfilled by the data (Figure 1E). Why is this so? At
doses below the ID50 more than half of the challenges fail
to establish an infection. In effect the incubation period data is
heavily censored to remove those individuals in whom the
challenge dose goes extinct. The challenges which, just by chance,
have slow initial growth are more likely to go extinct, or if they do
not will produce the largest incubation periods. Thus at low doses
the extinction process in the stochastic birth-death process censors
some very long incubation periods and disrupts the linear
relationship between dose and incubation period. At doses above
the ID50, most hosts become infected, thus censorship has less
effect and incubation periods correspond to those predicted by the
deterministic model – they decrease linearly with relative dose.
Figure 3A shows that the gradient of this part of the graph is
inversely proportion to the growth rate of prions. Figure 3B shows
that the expectation of the incubation period also increases as the
relative dose at the disease limit increases. Specifically, beyond
relative dose 0 the expectation of the incubation period is given by:
E(T)~ln(10) RDL{RD ðÞ =(b{m). The derivation for this
expression and the expression (Table S1), used to plot Figures 3A
and 3B, which describes how the expectation of the incubation
period changes with dose for all doses, is provided in Text S1 [34].
For those mice for which incubation period data were available
(N=2086) we grouped the mice according to relative dose
Figure 2. A stochastic model of prion replication. A) A
mathematical model of prion replication in which the number of
prions (n) changes according to a stochastic birth-death process. Prions
are ‘born’ at rate b per prion and ‘die’ at m per prion. B) In the model the
onset of disease occurs once the number of prions reaches a
predetermined ‘disease limit’ (L). An example of exponential prion
growth up to the disease limit is shown by the blue line. Alternatively,
by chance, the prion population can also become extinct and the host
is left uninfected (red line). For both of these examples the same initial
dose and model parameters are used. This model of a stochastic birth-
death process with two absorbing barriers (at n(t)=0) and n(t)=L) is a
well-studied problem called the ‘Gambler Ruin’ [22].
doi:10.1371/journal.pone.0023664.g002
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each dose (Table 1, column 7). These data are plotted in Figure 1E
and suggest that, as the model predicts, incubation period remains
invariant to dose below approximately relative dose 0. Above
relative dose 0 the data also follows the model prediction that the
average incubation period decreases linearly with relative dose.
Figure 1E shows the best fit of the model to the data. Least squares
is used for this calculation. Only two values need to be fitted: the
net growth rate of prions (b-m=0?07 days
21) and the relative dose
at the disease limit (RDL=10?3). In summary, the model predicts
that incubation period is invariant to dose at relative doses lower
than the ID50, but decreases linearly with relative dose at doses
above the ID50. The available murine scrapie data agrees with
these predictions.
Figure 3. Model predictions showing how the expectation and variance of the incubation period vary according to the relative
dose (RD), the net growth rate (b-m) and the relative dose at the disease limit (RDL). A) and B) show factors affecting the expectation of the
incubation period. The expected incubation period is approximately invariant to the inoculating dose for relative doses less than approximately 0 (the
ID50). Beyond approximately 0, the incubation period decreases linearly with relative dose. A) shows that the gradient of this slope is steeper if the
net growth rate of prions (b-m) is smaller. Specifically the gradient is equal to {ln(10)=(b{m). B) shows that the expectation of the incubation period
is also larger if the relative dose at the disease limit is larger. C) and D) show factors affecting the variance of the incubation period. The variance is
approximately invariant to dose for doses less than relative dose 0. Beyond 0 the variance decreases as the dose increases. The variance also increases
as the relative dose at the disease limit increases, but has an upper bound that is reached when the relative dose at the disease limit is greater than 3.
Thus the maximum variance is determined by the net growth rate (b-m). In panels A) and C) the relative dose at the disease limit is assumed to equal
4. In panels B) and D) the net growth rate is assumed to equal 0.06 days
21. We also assumed that at relative dose –2 there was 1 prion in the
population. This assumption truncates the graphs at relative dose –2, but does not change the shape of the graphs. The data included in this figure
are from 119 experiments for which an ID50 could be calculated.
doi:10.1371/journal.pone.0023664.g003
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by the model
Since TSE incubation periods are regarded as being highly
reproducible [6], we addressed the question: how does the
observed variation in incubation periods compare to the variation
predicted by the stochastic birth-death model. We derived an
analytic expression to describe how the variance of the incubation
period changes according to absolute dose (Table S1 and Text S1).
In Figures 3C and 3D these predictions are plotted on the rela-
tive dose scale where they show that, like the expectation of the
incubation period, variance is dependent only upon the relative
dose (RD), the net growth rate (b{m), and the relative dose at the
disease limit (RDL). Variance is invariant to dose for doses below
approximately the ID50, and decreases with dose above the ID50.
The variance is also larger if the relative dose at the disease limit is
larger (Figure 3D). However, if the dose at the disease limit is 1000
fold or more greater than the ID50 (RDL§3) then variance does
not increase any further. From the incubation period data we
estimate that RDL&10, implying that the expected variance will
be a function only of the net prion growth rate (b{m) (Figure 3C).
As described previously, this rate can be estimated from the mean
incubation period data.
We used the model and our estimate of the net growth rate (0.07
days
21) to predict the variance of the murine incubation periods at
different relative doses. This prediction is shown in Figure 1F
(black line). To compare it to the variance observed in the mice,
we considered two methods for evaluating variance. We first
grouped mice from all experiments according to relative dose and
then simply calculated the variance at each relative dose (Table 1,
column 8). At each dose the observed variance was considerably
greater than predicted. For example, at relative dose 0, the
predicted variance was 320 days, yet the observed variance was
17000 days.
To understand whether the high level of observed variability
was generated by variability between experiments, our second
calculation aimed to eliminate such inter-experiment variability.
For each dose within each experiment we first calculated the mean
incubation period. For dose-experiment ‘groups’ with two or more
infected mice with incubation period data (N=2032) for each
mouse we then calculated the difference between their incubation
period and the mean for their group. The ‘differences’ from each
experiment were then grouped according to relative dose and the
variance of these differences at each dose was calculated (Table 1,
column 9). These data are plotted in Figure 1F (circles). As
expected, they show that variability in incubation period decreases
with dose for doses beyond the ID50. They also hint that variance
may, as predicted, stabilise at doses lower than the ID50 –
variance is lower at relative dose –1 than at 0 – though there is no
clear pattern. However, the most striking observation is that the
observed variability is still much greater than the maximum
predicted variance, particularly so at low relative doses. For
example, at relative dose 0 the observed and predicted variances
were 2900 days and 320 days respectively. This difference cannot
be attributed to differential net growth rates between experiments.
When the six largest experiments are each considered individually
and net growth rates are calculated for each, the observed variance
is still much greater than predicted (Figure S2). In summary we
find that variability in incubation periods is much greater than
predicted by a simple stochastic birth-death process, even though
that model fits the data on infection probability and mean
incubation period rather well. Thus, although incubation periods
for prion diseases are remarkably reproducible in comparison with
other infections, they are nevertheless substantially less reliable
than if governed by a stochastic birth-death process.
The incubation period assay. Since end point titrations
take a long time and require large numbers of mice, a technique
called the ‘incubation period assay’ is now often used as an
alternative method for determining the TSE infectious doses
[32,33]. In this technique, end point titrations are first used to
calibrate the relationship between dose and incubation period.
Incubation period measurements are then compared to this
relationship to determine the dose of a sample, thereby saving both
time and resources. Our study provides new insight into the
relationship between dose and incubation period and therefore
into the capabilities, or rather limitations, of the incubation period
assay.
Our results imply that both the mean (Figure 1E) and variance
of the incubation period (Figure 1F) is invariant to dose for doses
below the ID50. This suggests that the incubation period assay
cannot be used to distinguish between different infectious doses
below the ID50. Consider, for example, one host infected with
a relative dose of –1 and one with a relative dose of –2. We predict
that both the mean and the variability of the incubation period at
each of these doses would be the same. Thus, incubation period
measurements from these hosts would provide no information to
distinguish between their infectious doses. We note, however, that
the incubation period assay should be capable of distinguishing –
with a level of certainty linked to the abundance and spread of data
used for calibration – between different doses above the ID50.
Discussion
In this study we first asked whether there exists a threshold dose
of prions below which the probability of infection is zero. By
comparing the scrapie dose-response curve observed in mice to
model predictions we found no evidence that such a threshold
exists. As the stochastic-birth death model predicts, the probability
of infection simply becomes smaller as the dose decreases.
Furthermore, we find evidence to support the assumption of a
linear relationship between dose and probability of infection in
assessing the risk from low dose exposure. Use of a linear relation
for doses above the ID50 will lead to overestimation of the risk.
Although we find no evidence of a threshold, it must be
emphasized that we cannot rule out this possibility. Though it was
to be expected because of the limited sample size, no mice were
infected at the lowest relative dose tested (–4), therefore a threshold
may exist at this dose or lower. However, acquiring data to
investigate this question further would require an unfeasibly large
number of test animals. Furthermore, the observation of infection
at a dose 1000 times more dilute than the ID50 shows that
infection is still possible at very low doses. In practical terms this is
low enough to regard there to be no safe dose.
Previous modelling work has focussed on understanding the
molecular form of a prion and its mechanism of replication. We
are not proposing a specific form or replication mechanism, rather
we ask whether data on infection probabilities are consistent with
the simplest model of replication that assumes no threshold dose. If
evidence did emerge of a threshold dose, one could tie it to the
hypothesis that the smallest infectious agent involved in TSEs (a
prion) is a polymer consisting of multiple PrP
Sc monomers above a
critical polymer length [4-6] . It is thought that such a polymer
replicates when it breaks into two or more polymers, each larger
than the critical length, before undergoing rapid monomer
addition. This is currently the most widely accepted mechanism
of prion replication. However, it is noteworthy that a threshold
polymer length is not the same as a threshold dose of prions, since
a prion is normally regarded as one infectious agent (i.e. a
polymer), not one PrP
Sc monomer. Dilution of infectious substrate
There Is No Safe Dose of Prions
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the critical polymer length, thus, the polymer breakage-addition
model of prion replication is consistent with our finding of no
threshold for infectiousness.
In this study we also asked how TSE incubation periods change
according to the inoculating dose. First, we asked whether it is true
that mean incubation period decreases linearly with logarithmic
decrease in dose. The model predicts that this relationship holds
only at doses higher than the ID50. For doses below the ID50,
mean incubation period is predicted to be invariant to dose. The
murine data are consistent with these predictions. This finding
delineates the situation in which there is a linear relationship
between dose and provides insight into the limitations of the
incubation period assay. Specifically, it suggests that the
incubation period assay should be unable to distinguish between
different doses below the ID50.
Second, we investigated variability in incubation periods and
asked whether TSE incubation periods are highly reproducible.
We revealed that they are markedly more variable than predicted
by the model. Our findings lead us to question why this is so,
especially given that the dose response curve and the mean
incubation periods are in close agreement with the model. Could
the mechanism of prion growth be incorrect or does the
inconsistency lie with data collection or the relationship between
prion numbers and clinical symptoms? The most popular model
for prion growth, based upon polymer breakage and expansion, is
underpinned by exponential growth dynamics and would predict
the same variability as seen here. That model therefore also cannot
explain the effect that we see. In regards to data collection, some
variability is likely to arise from the difficulty in spotting symptoms
and from small experimental variability in the dose of the
inoculum. It must also be noted that some inaccuracies in the data
could arise because the duration of the experiments was finite. At
the end of each experiment all surviving mice were culled
and examined for the presence of pathological lesion without
symptoms might have progressed to disease if the experiments had
run for longer. However this does not explain the high variability
in incubations periods as if the data were not censored in this way,
such unusually long incubation periods would only increase
variability, not reduce it.
It is not difficult to propose ways in which prion infection
is more complex than a stochastic birth-death process in a
homogeneous environment. All the heterogeneities of the in vivo
situation: spatial, tissue, temporal and genetic [35] could add to
the variability in incubation periods. It is indeed remarkable
that such a simple model so clearly reproduces the infection
probability and mean incubation period across thousands of mice
challenged under such a range of experimental conditions. The
intellectual challenge posed by this analysis is to understand what
processes are driving the observed variability in incubation
periods whilst conserving the infection probabilities and mean




The data used in this study were collated from 127 murine
scrapie titration experiments, conducted over 30 years (started
between 1965 and 1993). In these experiments each mouse was
inoculated with tissue from another mouse infected with a mouse-
passaged scrapie isolate. Within each experiment, the mice were
controlled for mouse breed, scrapie strain, route of inoculation
and the tissue from which the inoculum was derived. Between
experiments these variables differed such that ten different mouse
breeds and seven different scrapie strains were used. The
maximum duration of observation also differed between experi-
ments. In the majority of experiments, inoculation was intracranial
and the source of infectious material was usually brain; however
spleen tissue was occasionally used. In total, 4338 mice were
inoculated at varying doses (10 fold dilutions). For each mouse the
following information was recorded: 1) whether the animal was
killed or died, 2) the number of days between inoculation and
death and 3) whether there were clinical signs of scrapie at death.
For most mice pathological signs of scrapie were also tested post-
mortem. Depending upon the combination of the these factors,
each mouse was classified into one of the following categories: 1)
uninfected at the end of the experiment (N=1379), 2) infected
with incubation period data (N=2162), 3) infected without
incubation period data (i.e. they died or were killed before clinical
symptoms arose but were pathologically positive; N=57), or 4)
died prior to the end of the experiment not of scrapie (N=740).
The precise rules defining these categories, and more details of
these experiments are provided in McLean and Bostock [17]. It
was highlighted in that report that there is there are no systematic
trends that render comparison across the 30 years of experiments
invalid. Following estimation of the ID50 for each experiment
(explained in Figure S1) eight experiments (195 mice) were
removed from further analysis. Data from the remaining 119
experiments are presented in Figure 1 and Table 1.
Supporting Information
Figure S1 Calculating the ID50 for each experiment.
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Figure S2 For each of the six largest experiments, the
observed variance of the incubation period is markedly
larger than the maximum predicted variance.
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Table S1 Analytic expressions derived from the stochastic model
describing the probability of infection and the expectation and
variance of incubation period.
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Text S1 Derivations for analytic expressions describing the
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